Biogen Idec (BIIB) Enrolls First Patient in Phase III Trial for ALS Treatment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/1/2026

1. SPY
2. MDT
3. ENOV
4. AON
5. AZN
6. BLSM
7. GPRO
8. KRMN
9. SPGI
10. GRMN

Go back to Biogen Idec (BIIB) Enrolls First Patient in Phase III Trial for ALS Treatment
BIOGEN IDEC Inc. (NASDAQ: BIIB) Delayed: 215.99 -0.66 (0.3%)
Previous Close $216.65    52 Week High $333.65 
Open $218.11    52 Week Low $223.02 
Day High $219.30    P/E 27.66 
Day Low $215.37    EPS $7.81 
Volume 211,214